is tirzepatide a glp 1 or 2 Management of type diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: systematic review and meta-analysis | Diabetologia The dual agonist action of

10 GLP-1 receptor agonists (GLP-1RAs), or incretin mimetics, are currently among the most promising drugs for adjusting metabolic function, playing significant roles in the management of T2DM, and some have been approved for obesity management

Much excitement surrounds molecules which target multiple incretin receptors simultaneously, such as GLP-1-GIP co-agonists and molecules which both agonize the GLP-1R and antagonize the GIPR

Emerging research on microdosing GLP-1 agonists for autoimmune conditions suggests potential immunomodulatory effects, though this area remains early in investigation

In a chronic social defeat stress model in mice, 21 days of oral administration at 0.1 mg/kg corrected depressive-like behavior, restored motor activity with a therapeutic effect of 60 percent, completely recovered anhedonia, restored synaptophysin levels (74 percent therapeutic effect), and fully restored CREB levels in the hippocampus